Market Overview

UPDATE: Goldman Sachs Reduces PT to $16 on MAKO Surgical Following Common Stock Offering

Related MAKO
Credit Suisse Adjusts Estimates and PT on Stryker Following MAKO Acquisition
Benzinga's Top Downgrades

Goldman Sachs reiterated its Neutral rating on MAKO Surgical (NASDAQ: MAKO) and reduced its price target from $17 to $16.

Goldman Sachs noted, "On Wednesday, November 14, MAKO Surgical completed a common stock offering of 3.04mn shares at $13.15 per share. This compares to the November 13 closing price of $13.21. We note that shares of MAKO were down 9.1% on November 13 vs. the Russell 2000 down 0.6% ahead of the company's announced offering that was issued after the market close. We update our model for a higher share count as well as the cash inflow associated with the secondary share issuance (approximately $45mn). … The completed financing removes a risk, as the company should maintain a cash cushion."

MAKO Surgical closed at $13.21 on Tuesday.

Posted-In: Goldman SachsAnalyst Color Price Target Intraday Update Analyst Ratings

 

Most Popular

Related Articles (MAKO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free